PharmaCyte Biotech approves reverse stock split
The company approved a 1-for-19 reverse stock split and filed the amendment on Nov. 12, 2026. The change is a regulatory step often taken by companies to meet listing requirements.
AI-generated summary for informational purposes only. Always verify against the original filing. Not investment advice. BriefTape is not a registered investment adviser.
Get real-time financial news in your trading bot or app
START FREE — 10,000 calls/day, no key needed